Switch theme
Sign up to access all valuation multiples
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need. It operates in United States of America.
2006
139
LTM Revenue $60.9M
LTM EBITDA -$462M
-$45.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nykode Therapeutics has a last 12-month revenue (LTM) of $60.9M and a last 12-month EBITDA of -$462M.
In the most recent fiscal year, Nykode Therapeutics achieved revenue of $0.8M and an EBITDA of -$4.2M.
Nykode Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nykode Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $60.9M | XXX | $0.8M | XXX | XXX | XXX |
| Gross Profit | $60.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$462M | XXX | -$4.2M | XXX | XXX | XXX |
| EBITDA Margin | -758% | XXX | -496% | XXX | XXX | XXX |
| EBIT | -$458M | XXX | -$4.7M | XXX | XXX | XXX |
| EBIT Margin | -753% | XXX | -557% | XXX | XXX | XXX |
| Net Profit | -$422M | XXX | -$3.8M | XXX | XXX | XXX |
| Net Margin | -693% | XXX | -447% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nykode Therapeutics's stock price is NOK 2 (or $0).
Nykode Therapeutics has current market cap of NOK 584M (or $57.0M), and EV of -NOK 470M (or -$45.9M).
See Nykode Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$45.9M | $57.0M | XXX | XXX | XXX | XXX | $-0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nykode Therapeutics has market cap of $57.0M and EV of -$45.9M.
Nykode Therapeutics's trades at -54.1x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate Nykode Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nykode Therapeutics has a P/E ratio of -1.4x.
See valuation multiples for Nykode Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $57.0M | XXX | $57.0M | XXX | XXX | XXX |
| EV (current) | -$45.9M | XXX | -$45.9M | XXX | XXX | XXX |
| EV/Revenue | -7.7x | XXX | -54.1x | XXX | XXX | XXX |
| EV/EBITDA | 1.0x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 1.0x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | -7.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -15.0x | XXX | XXX | XXX |
| EV/FCF | 1.1x | XXX | 9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNykode Therapeutics's last 12 month revenue growth is -57%
Nykode Therapeutics's revenue per employee in the last FY averaged $6K, while opex per employee averaged $40K for the same period.
Nykode Therapeutics's rule of 40 is -380% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nykode Therapeutics's rule of X is -900% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nykode Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -57% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -758% | XXX | -496% | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | 186% | XXX | XXX | XXX |
| Rule of 40 | -380% | XXX | -553% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -900% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $6K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $40K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 170% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 657% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nykode Therapeutics acquired XXX companies to date.
Last acquisition by Nykode Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Nykode Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nykode Therapeutics founded? | Nykode Therapeutics was founded in 2006. |
| Where is Nykode Therapeutics headquartered? | Nykode Therapeutics is headquartered in Norway. |
| How many employees does Nykode Therapeutics have? | As of today, Nykode Therapeutics has 139 employees. |
| Who is the CEO of Nykode Therapeutics? | Nykode Therapeutics's CEO is Mr. Michael Thyrring Engsig. |
| Is Nykode Therapeutics publicy listed? | Yes, Nykode Therapeutics is a public company listed on OSL. |
| What is the stock symbol of Nykode Therapeutics? | Nykode Therapeutics trades under NYKD ticker. |
| When did Nykode Therapeutics go public? | Nykode Therapeutics went public in 2020. |
| Who are competitors of Nykode Therapeutics? | Similar companies to Nykode Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Nykode Therapeutics? | Nykode Therapeutics's current market cap is $57.0M |
| What is the current revenue of Nykode Therapeutics? | Nykode Therapeutics's last 12 months revenue is $60.9M. |
| What is the current revenue growth of Nykode Therapeutics? | Nykode Therapeutics revenue growth (NTM/LTM) is -57%. |
| What is the current EV/Revenue multiple of Nykode Therapeutics? | Current revenue multiple of Nykode Therapeutics is -7.7x. |
| Is Nykode Therapeutics profitable? | Yes, Nykode Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nykode Therapeutics? | Nykode Therapeutics's last 12 months EBITDA is -$462M. |
| What is Nykode Therapeutics's EBITDA margin? | Nykode Therapeutics's last 12 months EBITDA margin is -758%. |
| What is the current EV/EBITDA multiple of Nykode Therapeutics? | Current EBITDA multiple of Nykode Therapeutics is 1.0x. |
| What is the current FCF of Nykode Therapeutics? | Nykode Therapeutics's last 12 months FCF is -$418M. |
| What is Nykode Therapeutics's FCF margin? | Nykode Therapeutics's last 12 months FCF margin is -687%. |
| What is the current EV/FCF multiple of Nykode Therapeutics? | Current FCF multiple of Nykode Therapeutics is 1.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
